MediGene AG (ETR:MDG1) PT Set at €12.00 by Oddo Securities

MediGene AG (ETR:MDG1) has been given a €12.00 ($14.12) target price by equities research analysts at Oddo Securities in a research note issued on Tuesday. The firm currently has a “buy” rating on the stock.

A number of other equities analysts have also commented on MDG1. Independent Research GmbH set a €12.00 ($14.12) price target on shares of MediGene AG and gave the stock a “neutral” rating in a research report on Saturday, May 20th. Baader Bank set a €19.00 ($22.35) price target on shares of MediGene AG and gave the stock a “buy” rating in a research report on Saturday, May 20th.

Shares of MediGene AG (ETR:MDG1) opened at 9.82 on Tuesday. MediGene AG has a 12 month low of €6.65 and a 12 month high of €15.19. The stock’s 50 day moving average is €10.81 and its 200 day moving average is €11.64. The firm’s market capitalization is €197.85 million.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://sportsperspectives.com/2017/08/10/medigene-ag-etrmdg1-pt-set-at-12-00-by-oddo-securities.html.

About MediGene AG

Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors.

Receive News & Ratings for MediGene AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediGene AG and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply